The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Analgesic Effect of Intrathecal Ginsenosides in a Murine Bone Cancer Pain

  • Yoon, Myung-Ha (Department of Anesthesiology and Pain Medicine, Chonnam National University, Medical School) ;
  • Kim, Woong-Mo (Department of Anesthesiology and Pain Medicine, Chonnam National University, Medical School) ;
  • Lee, Hyung-Gon (Department of Anesthesiology and Pain Medicine, Chonnam National University, Medical School) ;
  • Choi, Jeong-Il (Department of Anesthesiology and Pain Medicine, Chonnam National University, Medical School) ;
  • Kim, Yeo-Ok (Department of Anesthesiology and Pain Medicine, Chonnam National University, Medical School) ;
  • Song, Ji-A (Department of Anesthesiology and Pain Medicine, Chonnam National University, Medical School)
  • Received : 2010.09.06
  • Accepted : 2010.10.13
  • Published : 2010.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Bone cancer pain has a disruptive effect on the cancer patient's quality of life. Although ginsenosides have been used as traditional medicine in Eastern Medicine, the effect on bone cancer pain has not been throughly studied. The aim of this study was to determine whether ginsenosides may alter the bone cancer pain at the spinal level. Methods: NCTC 2472 tumor cells ($2.5{\times}10^5$) were injected into the femur of adult male C3H/HeJ mice to evoke bone tumor and bone cancer pain. To develop bone tumor, radiologic pictures were obtained. To assess pain, the withdrawal thereshold was measured by applying a von Frey filament to the tumor cells inoculation site. The effect of intrathecal ginsenosides was investigated. Effect of ginsenosides (150, 500, $1,000{\mu}g$) was examined at 15, 30, 60, 90, 120 min after intrathecal delivery. Results: The intrafemoral injection of NCTC 2472 tumor cells induced a radiological bone tumor. The withdrawal threshold with tumor development was significantly decreased compared to the sham animals. Intrathecal ginsenosides effectively increased the withdrawal threshold in the bone cancer site. Conclusions: NCTC 2472 tumor cells injection into the mice femur caused bone tumor and bone cancer pain. Intrathecal ginsenosides attenuated the bone cancer-related pain behavior. Therefore, spinal ginsenosides may be an alternative analgesic for treating bone cancer pain.

Keywords

References

  1. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999; 353: 1695-700. https://doi.org/10.1016/S0140-6736(99)01310-0
  2. Banning A, Sjogren P, Henriksen H. Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain 1991; 45: 45-8. https://doi.org/10.1016/0304-3959(91)90163-R
  3. Coleman RE, Houston S, Purohit OP, Rubens RD, Kandra A, Ford J. A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. Eur J Cancer 1998; 34: 820-4. https://doi.org/10.1016/S0959-8049(97)10155-1
  4. Coleman RE. How can we improve the treatment of bone metastases further? Curr Opin Oncol 1998; 10(Suppl 1): S7-13.
  5. Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 1998; 24: 425-32. https://doi.org/10.1016/S0305-7372(98)90005-6
  6. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69: 1-18. https://doi.org/10.1016/S0304-3959(96)03267-8
  7. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999; 81: 129-34. https://doi.org/10.1016/S0304-3959(99)00006-8
  8. Mercadante S, Fulfaro F. Management of painful bone metastases. Curr Opin Oncol 2007; 19: 308-14. https://doi.org/10.1097/CCO.0b013e3281214400
  9. O'Connor JP, Lysz T. Celecoxib, NSAIDs and the skeleton. Drugs Today (Barc) 2008; 44: 693-709. https://doi.org/10.1358/dot.2008.44.9.1251573
  10. Vanderah TW, Gardell LR, Burgess SE, Ibrahim M, Dogrul A, Zhong CM, et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci 2000; 20: 7074-9.
  11. Liu CX, Xiao PG. Recent advances on ginseng research in China. J Ethnopharmacol 1992; 36: 27-38. https://doi.org/10.1016/0378-8741(92)90057-X
  12. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999; 58: 1685-93. https://doi.org/10.1016/S0006-2952(99)00212-9
  13. Nah JJ, Hahn JH, Chung S, Choi S, Kim YI, Nah SY. Effect of ginsenosides, active components of ginseng, on capsaicin-induced pain-related behavior. Neuropharmacology 2000; 39: 2180-4. https://doi.org/10.1016/S0028-3908(00)00048-4
  14. Shin DJ, Yoon MH, Lee HG, Kim WM, Park BY, Kim YO, et al. The effect of treatment with intrathecal ginsenosides in a rat model of postoperative pain. Korean J Pain 2007; 20: 100-5. https://doi.org/10.3344/kjp.2007.20.2.100
  15. Kim SY, Yoon MH, Lee HG, Kim WM, Lee JD, Kim YO, et al. The role of adrenergic and cholinergic receptors on the antinociception of Korean red ginseng in the spinal cord of rats. Korean J Pain 2008; 21: 27-32. https://doi.org/10.3344/kjp.2008.21.1.27
  16. Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999; 19: 10886-97.
  17. Hylden JL, Wilcox GL. Intrathecal morphine in mice: a new technique. Eur J Pharmacol 1980; 67: 313-6. https://doi.org/10.1016/0014-2999(80)90515-4
  18. Dixon WJ. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 1980; 20: 441-62. https://doi.org/10.1146/annurev.pa.20.040180.002301
  19. Yoon MH, Choi JI, Jeong SW. Antinociception of intrathecal cholinesterase inhibitors and cholinergic receptors in rats. Acta Anaesthesiol Scand 2003; 47: 1079-84. https://doi.org/10.1034/j.1399-6576.2003.00212.x
  20. Nah SY. Ginseng; recent advances and trends. Korean J Ginseng Sci 1997; 21: 1-12.
  21. Kaku T, Miyata T, Uruno T, Sako I, Kinoshita A. Chemicopharmacological studies on saponins of Panax ginseng C. A. Meyer. II. Pharmacological part. Arzneimittelforschung 1975; 25: 539-47.
  22. Lee JH, Jeong SM, Lee BH, Kim DH, Kim JH, Kim JI, et al. Differential effect of bovine serum albumin on ginsenoside metabolite-induced inhibition of alpha3beta4 nicotinic acetylcholine receptor expressed in Xenopus oocytes. Arch Pharm Res 2003; 26: 868-73. https://doi.org/10.1007/BF02980034
  23. Nah SY, McCleskey EW. Ginseng root extract inhibits calcium channels in rat sensory neurons through a similar path, but different receptor, as mu-type opioids. J Ethnopharmacol 1994; 42: 45-51. https://doi.org/10.1016/0378-8741(94)90022-1
  24. Nah SY, Park HJ, McCleskey EW. A trace component of ginseng that inhibits Ca2+ channels through a pertussis toxin-sensitive G protein. Proc Natl Acad Sci USA 1995; 92: 8739-43. https://doi.org/10.1073/pnas.92.19.8739
  25. Rhim H, Kim H, Lee DY, Oh TH, Nah SY. Ginseng and ginsenoside Rg3, a newly identified active ingredient of ginseng, modulate Ca2+ channel currents in rat sensory neurons. Eur J Pharmacol 2002; 436: 151-8. https://doi.org/10.1016/S0014-2999(01)01613-2
  26. Shin YH, Jung OM, Nah JJ, Nam KY, Kim CY, Nah SY. Ginsenosides that produce differential antinociception in mice. Gen Pharmacol 1999; 32: 653-9. https://doi.org/10.1016/S0306-3623(98)00239-0

Cited by

  1. Assessment and refinement of intra-bone marrow transplantation in mice vol.49, pp.2, 2015, https://doi.org/10.1177/0023677214559627
  2. Ginsenoside Rf relieves mechanical hypersensitivity, depression-like behavior, and inflammatory reactions in chronic constriction injury rats pp.0951418X, 2019, https://doi.org/10.1002/ptr.6303
  3. Antinociceptive effects of Ginsenoside Rb1 in a rat model of cancer-induced bone pain vol.17, pp.5, 2010, https://doi.org/10.3892/etm.2019.7404
  4. Intra-iliac bone marrow injection as a novel alternative to intra-tibial inoculation in rat model vol.12, pp.1, 2010, https://doi.org/10.1186/s13287-021-02413-7